Yıl: 2024 Cilt: 20 Sayı: 1 Sayfa Aralığı: 42 - 47 Metin Dili: İngilizce DOI: 10.4274/BMJ.galenos.2023.2022.5-12 İndeks Tarihi: 10-06-2024

Prevalence and Prognostic Significance of Anemia in Lymphoma

Öz:
Objective: Anemia is common in cancer patients and has adverse effects on prognosis. In this study, we investigated the prevalence, etiological causes, and effects of anemia on the prognosis of patients with lymphoma. Methods: We analyzed 153 newly diagnosed lymphoma cases. The hemoglobin (Hb) cut-off value for the diagnosis of anemia was set as Hb <12 g/dL in women and Hb <13 g/dL in men. Cases with anemia were classified as mild (Hb =10 g/dL-normal value), moderate (Hb =8-9.9 g/dL), and severe (Hb <8 g/dL) anemia. The relationship between the presence and degree of anemia and the revised international prognostic index (r-IPI) score, Eastern Cooperative Oncology Group performance score, Ann Arbor stage, presence of B symptoms, bulky mass, extra-nodal involvement, and life status was evaluated. Results: Anemia was detected in 82 (53.6%) patients, and the most common cause of anemia was chronic disease anemia (30.5%). There was no significant relationship between the presence of anemia and the presence of bulky mass, r-IPI score, performance score, or Ann Arbor stage. A significant correlation was found between the degree of anemia and the presence of extranodal involvement and B symptoms (p<0.001, p=0.01, respectively). A significant correlation was found between the presence and degree of anemia and overall survival (p=0.011, p<0.001, respectively). Conclusion: Anemia is common in Hodgkin and diffuse large B-cell lymphoma patients and is associated with some worse prognostic factors. Therefore, further studies examining more cases and including patients in all non-Hodgkin lymphoma subgroups are needed to better understand the importance of anemia in lymphoma cases.
Anahtar Kelime:

Lenfomada Aneminin Prevalansı ve Prognostik Önemi

Öz:
Amaç: Anemi kanser hastalarında sık görülür ve prognozu olumsuz etkiler. Bu çalışmada lenfoma hastalarında aneminin prevalansını, etiyolojik nedenlerini ve prognoz üzerindeki etkilerini araştırmayı amaçladık. Gereç ve Yöntem: Yeni tanı almış 153 lenfoma olgusunu inceledik. Anemi tanısı için hemoglobin (Hb) eşik değeri kadınlarda Hb <12 g/dL, erkeklerde Hb <13 g/dL olarak kabul edildi. Anemisi olan olgular hafif (Hb =10 g/dL-normal değer), orta (Hb =8-9,9 g/dL) ve şiddetli (Hb <8 g/dL) anemi olarak sınıflandırıldı. Anemi varlığı ve derecesi ile revize edilmiş uluslararası prognostik indeks (r-IPI) skoru, Eastern Cooperative Oncology Group performans skoru, Ann Arbor evresi, B semptom varlığı, hacimli kitle, ekstra nodal tutulum ve yaşam durumu arasındaki ilişki değerlendirildi. Bulgular: Seksen iki (%53,6) olguda anemi saptandı ve aneminin en sık nedeni kronik hastalık anemisiydi (%30,5). Anemi varlığı ile hacimli kitle varlığı, r-IPI skoru, performans skoru, Ann Arbor evresi arasında anlamlı bir ilişki yoktu. Anemi derecesi ile ekstranodal tutulum ve B semptomlarının varlığı arasında anlamlı bir ilişki bulundu (sırasıyla p<0,001, p=0,01). Anemi varlığı ve derecesi ile genel sağkalım arasında anlamlı bir korelasyon bulundu (sırasıyla p=0,011, p<0,001). Sonuç: Hodgkin ve diffüz büyük B-hücreli lenfoma hastalarında anemi sıktır ve bazı kötü prognostik faktörlerle ilişkilidir. Bu nedenle lenfoma olgularında aneminin öneminin daha iyi anlaşılabilmesi için daha fazla olguyu inceleyen ve Hodgkin dışı lenfomanın tüm alt gruplarındaki hastaları içeren ileri çalışmalara ihtiyaç vardır.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
0
0
0
  • 1. İliçin G, Biberoğlu K, Süleymanlar G, Ünal S. İç Hastalıkları. 2. Baskı. Ankara: Güneş Kitabevi; 2003.
  • 2. Eisenstaedt R, Penninx BW, Woodman RC. Anemia in the elderly: current understanding and emerging concepts. Blood Rev 2006;20:213-26.
  • 3. Gardner W, Kassebaum N. Global, Regional, and National Prevalence of Anemia and Its Causes in 204 Countries and Territories, 1990-2019. Curr Dev Nutr 2020;4(Suppl 2):830.
  • 4. Knight K, Wade S, Balducci L. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med 2004;116(Suppl 7A):11-26.
  • 5. Birgegård G, Gascón P, Ludwig H. Evaluation of anemia in patients with multiple myeloma and lymphoma: findings of the European Cancer Anaemia Survey. Euro J Haematol 2006;77:378-86.
  • 6. Birgegård G, Aapro MS, Bokemeyer C, Dicato M, Drings P, Hornedo J, et al. Cancer-related anemia: pathogenesis, prevalence and treatment. Oncology 2005;68(Suppl 1):3-11.
  • 7. Ghosh J, Singh RK, Saxena R, Gupta R, Vivekanandan S, Sreenivas V, et al. Prevalence and aetiology of anaemia in lymphoid malignancies. Natl Med J India 2013;26:79-81.
  • 8. Abuzallouf S, Vasishta S, Ragheb A, Varghese A, El-Hattab O. Prognostic value of hemoglobin levels prior to radiotherapy for cervical cancer--Kuwait experience. Gulf J Oncolog 2008;3:41-45.
  • 9. Grotto HZ. Anaemia of cancer: an overview of mechanisms involved in its pathogenesis. Med Oncol 2008;25:12-21.
  • 10. Moullet I, Salles G, Ketterer N, Dumontet C, Bouafia F, Neidhart- Berard EM, et al. Frequency and significance of anemia in non- Hodgkin's lymphoma patients Ann Oncol 1998;9:1109-15.
  • 11. Morel P, Lepage E, Brice P, Dupriez B, D'Agay MF, Fenaux P, et al. Prognosis and treatment of lymphoblastic lymphoma in adults:a report on 80 patients. J Clin Oncol 1992;10:1078-85.
  • 12. Yasmeen T, Ali J, Khan K, Siddiqui N. Frequency and causes of anemia in Lymphoma patients. Pak J Med Sci 2019;35:61-5.
  • 13. Kifle E, Hussein M, Alemu J, Tigeneh W. Prevalence of Anemia and Associated Factors among Newly Diagnosed Patients with Solid Malignancy at Tikur Anbessa Specialized Hospital, Radiotherapy Center, Addis Ababa, Ethiopia. Adv Hematol 2019;2019:8279789.
  • 14. Sallah S, Sigounas G, Vos P, Wan JY, Nguyen NP. Autoimmune hemolytic anemia in patients with non-Hodgkin's lymphoma: characteristics and significance. Ann Oncol 2000;11:1571-7.
  • 15. Zhou JC, Wu MQ, Peng ZM, Zhao WH, Bai ZJ. Clinical analysis of 20 patients with non-Hodgkin lymphoma and autoimmune hemolytic anemia: A retrospective study. Medicine (Baltimore 2020;99:19015.
  • 16. Morrow TJ, Volpe S, Gupta S, Tannous RE, Fridman M. Anemia of cancer in intermediate-grade non-Hodgkin's lymphoma. South Med J 2002;95:889-96.
  • 17. Bremnes RM, Bremnes Y, Dønnem T. High-grade non-Hodgkin's lymphoma treated in northern Norway--treatment, outcome, and prognostic factors. Acta Oncol 1999;38:117-24.
APA SİNCAN g, KILIÇ A, SINCAN S, erdem f (2024). Prevalence and Prognostic Significance of Anemia in Lymphoma. , 42 - 47. 10.4274/BMJ.galenos.2023.2022.5-12
Chicago SİNCAN gulden,KILIÇ ADİL FURKAN,SINCAN Suat,erdem fuat Prevalence and Prognostic Significance of Anemia in Lymphoma. (2024): 42 - 47. 10.4274/BMJ.galenos.2023.2022.5-12
MLA SİNCAN gulden,KILIÇ ADİL FURKAN,SINCAN Suat,erdem fuat Prevalence and Prognostic Significance of Anemia in Lymphoma. , 2024, ss.42 - 47. 10.4274/BMJ.galenos.2023.2022.5-12
AMA SİNCAN g,KILIÇ A,SINCAN S,erdem f Prevalence and Prognostic Significance of Anemia in Lymphoma. . 2024; 42 - 47. 10.4274/BMJ.galenos.2023.2022.5-12
Vancouver SİNCAN g,KILIÇ A,SINCAN S,erdem f Prevalence and Prognostic Significance of Anemia in Lymphoma. . 2024; 42 - 47. 10.4274/BMJ.galenos.2023.2022.5-12
IEEE SİNCAN g,KILIÇ A,SINCAN S,erdem f "Prevalence and Prognostic Significance of Anemia in Lymphoma." , ss.42 - 47, 2024. 10.4274/BMJ.galenos.2023.2022.5-12
ISNAD SİNCAN, gulden vd. "Prevalence and Prognostic Significance of Anemia in Lymphoma". (2024), 42-47. https://doi.org/10.4274/BMJ.galenos.2023.2022.5-12
APA SİNCAN g, KILIÇ A, SINCAN S, erdem f (2024). Prevalence and Prognostic Significance of Anemia in Lymphoma. Bakırköy Tıp Dergisi, 20(1), 42 - 47. 10.4274/BMJ.galenos.2023.2022.5-12
Chicago SİNCAN gulden,KILIÇ ADİL FURKAN,SINCAN Suat,erdem fuat Prevalence and Prognostic Significance of Anemia in Lymphoma. Bakırköy Tıp Dergisi 20, no.1 (2024): 42 - 47. 10.4274/BMJ.galenos.2023.2022.5-12
MLA SİNCAN gulden,KILIÇ ADİL FURKAN,SINCAN Suat,erdem fuat Prevalence and Prognostic Significance of Anemia in Lymphoma. Bakırköy Tıp Dergisi, vol.20, no.1, 2024, ss.42 - 47. 10.4274/BMJ.galenos.2023.2022.5-12
AMA SİNCAN g,KILIÇ A,SINCAN S,erdem f Prevalence and Prognostic Significance of Anemia in Lymphoma. Bakırköy Tıp Dergisi. 2024; 20(1): 42 - 47. 10.4274/BMJ.galenos.2023.2022.5-12
Vancouver SİNCAN g,KILIÇ A,SINCAN S,erdem f Prevalence and Prognostic Significance of Anemia in Lymphoma. Bakırköy Tıp Dergisi. 2024; 20(1): 42 - 47. 10.4274/BMJ.galenos.2023.2022.5-12
IEEE SİNCAN g,KILIÇ A,SINCAN S,erdem f "Prevalence and Prognostic Significance of Anemia in Lymphoma." Bakırköy Tıp Dergisi, 20, ss.42 - 47, 2024. 10.4274/BMJ.galenos.2023.2022.5-12
ISNAD SİNCAN, gulden vd. "Prevalence and Prognostic Significance of Anemia in Lymphoma". Bakırköy Tıp Dergisi 20/1 (2024), 42-47. https://doi.org/10.4274/BMJ.galenos.2023.2022.5-12